Detalhe da pesquisa
1.
Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css-MRTpo method and chimeric mice with humanised livers.
Xenobiotica
; 53(8-9): 523-535, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37938160
2.
Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets.
Xenobiotica
; 52(6): 613-624, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36148579
3.
Empirical and theoretical approaches for the prediction of human hepatic clearance using chimeric mice with humanised liver: the use of physiologically based scaling, a novel solution for potential overprediction due to coexisting mouse metabolism.
Xenobiotica
; 51(9): 983-994, 2021 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34227923
4.
Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets from common marmosets genotyped for P450 2C19.
Xenobiotica
; 51(4): 479-493, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33455494
5.
A novel Css-MRTpo approach to simulate oral plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using chimeric mice with humanized livers.
Xenobiotica
; 50(7): 761-768, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-31721621
6.
Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling.
Xenobiotica
; 47(5): 382-393, 2017 May.
Artigo
Inglês
| MEDLINE | ID: mdl-27389028
7.
Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound.
Xenobiotica
; 46(6): 557-69, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-26444900
8.
Murine Cyp3a knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans.
Biopharm Drug Dispos
; 37(1): 3-14, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-26352195
9.
Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers.
Drug Metab Dispos
; 43(3): 309-16, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25504502
10.
Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver.
Drug Metab Dispos
; 43(8): 1208-17, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-25979261
11.
Formation of reactive metabolites of benzbromarone in humanized-liver mice.
Drug Metab Pharmacokinet
; 47: 100467, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36223709
12.
An improved TK-NOG mouse as a novel platform for humanized liver that overcomes limitations in both male and female animals.
Drug Metab Pharmacokinet
; 42: 100410, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34839181
13.
Humanized liver TK-NOG mice with functional deletion of hepatic murine cytochrome P450s as a model for studying human drug metabolism.
Sci Rep
; 12(1): 14907, 2022 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36050438
14.
Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Drug Metab Dispos
; 38(1): 1-4, 2010 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-19833842
15.
Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro.
Drug Metab Dispos
; 38(2): 249-59, 2010 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-19889885
16.
Human plasma concentration-time profiles of troglitazone and troglitazone sulfate simulated by in vivo experiments with chimeric mice with humanized livers and semi-physiological pharmacokinetic modeling.
Drug Metab Pharmacokinet
; 35(6): 505-514, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-32962912
17.
Predicted values for human total clearance of a variety of typical compounds with differently humanized-liver mouse plasma data.
Drug Metab Pharmacokinet
; 35(4): 389-396, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32690433
18.
Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant.
Drug Metab Dispos
; 37(9): 1856-63, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19520775
19.
Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells.
Drug Metab Dispos
; 37(3): 619-28, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19056913
20.
Relationship between exposure of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a "funny" if current channel inhibitor, and heart rate reduction in tachycardia-induced beagle dogs.
Drug Metab Dispos
; 37(7): 1427-33, 2009 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-19359407